Moderna rises after reporting more funding, Hasbro falls following Q2 earnings miss Check out this morning's top movers from around Wall Street, compiled by The Fly.
HIGHER -
- Moderna (MRNA) up 8% after announcing a modification to its contract with the Biomedical Advanced Research and Development Authority for an additional commitment of up to $472M to support late stage clinical development including the expanded Phase 3 study of the company's mRNA vaccine candidate against COVID-19
- MediciNova (MNOV) up 16% after announcing an agreement with BioComo and Mie University for joint development of a SARS-CoV-2 vaccine using BC-PIV, a human parainfluenza virus type 2 vector
UP AFTER EARNINGS -
- SAP (SAP) up 2%
- Avery Dennison (AVY) up 1%
- RPM (RPM) up 1%
DOWN AFTER EARNINGS -
ALSO LOWER -
- Under Armour (UA) down 3% after disclosing that Kevin Plank, the company's executive chairman and brand chief, and David Bergman, the company's CFO, received a "Wells Notice" from the staff of the SEC relating to the company's previously-disclosed SEC investigation
- eMagin (EMAN) down 5% after confirming the award of a $33.6M contract over the next 33 months from the Department of Defense to sustain and enhance U.S. domestic capability for OLED microdisplays that will be based on eMagin's proprietary direct patterning technology
- Lemonade (LMND) down 4% after analysts rolled out coverage, including Goldman Sachs analyst Heath Terry starting coverage with a Sell rating and $44 price target
Symbols:
MRNA MNOV SAP AVY - $120.38 /
-0.505 (-0.42%)
RPM HAS UA EMAN LMND UAA Keywords: Fly Intel, Wall Street, Top Stories, Stocks